Pall Life Sciences wins BPI 2016 Best Downstream Application Award

Cadence Acoustic Separator system is a novel single-use solution for the clarification of cell culture bioprocess fluids.
Pall Life Sciences, a division of Pall Corporation,has won the BioProcess International (BPI) Award for best downstream processing application for the Cadence Acoustic Separator. Celebrated bi-annually since 2012, the BPI Awards are hosted during the BioProcess International Conference in Boston, MA. The awards exist to celebrate outstanding individual and team achievements that allow the industry to deliver better, more effective treatments to a global patient base.
Based on acoustic wave separation technology licensed from FloDesign Sonics, the Cadence Acoustic Separator was launched in early 2016 as a novel single-use solution for the clarification of cell culture bioprocess fluids. The system is a robust platform technology that enables continuous cell separation without centrifugation and dramatically reduced filtration steps for cost-effective preconditioning of the clarified cell culture fluid for downstream processes. The technology can also be fully integrated with Pall’s portfolio of continuous downstream bioprocessing technologies.
“We are honored by the recognition of the Cadence Acoustic Separator in 2016, but it is particularly exciting to win this award,” said Michael Egholm, VP & General Manager of Pall Biopharmaceuticals. “We first introduced the concept of acoustic wave separation for biopharmaceutical applications at last year’s BPI 2015 conference, with the intention of launching in 2016. Thank you to my team, and the team at FloDesign Sonics for partnering with us to develop and launch such a game-changing technology.”
Earlier this year, the Cadence Acoustic Separator technology was awarded second prize for Innovation in an open vote on submitted posters at the Recovery of Biological Products XVII Conference in Bermuda, as well as featured in Pharmaceutical Manufacturing as a 2016 Star Innovation.
The Cadence Acoustic Separator technology is on display in booth 521 at BPI 2016 this week, among a portfolio of enabling Pall Life Sciences technologies. The displays demonstrate scale up for the clarification application, and a process development approach for perfusion with the AWS technology. Both applications are set to be launched in 2017.
Related News
-
News CPHI Online Trend Report – 2025 Pharma Packaging Prospects
The pharmaceutical packaging market has seen marked shifts in innovations, priorities, and focus over the last few years. With the rise of hit drugs like GLP-1 agonists and biologics requiring specialised packaging considerations, the strain of meeting... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance